Technical Analysis for AKTX - Akari Therapeutics Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 11 hours ago |
| Down 5% | about 11 hours ago |
| Down 3% | about 11 hours ago |
| Fell Below Previous Day's Low | about 11 hours ago |
| Down 2 % | about 11 hours ago |
Get a Trading Sidekick!
- Earnings date: 04/29/2024
Akari Therapeutics Plc Description
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Organ Systems Rare Diseases Inflammatory Diseases Autoimmunity Autoimmune And Inflammatory Disease Complement System Myasthenia Gravis Myasthenia Acquired Hemolytic Anemia Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria C5a Hemolytic Uremic Syndrome Sjögren's Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.5 |
| 52 Week Low | 1.0775 |
| Average Volume | 19,495 |
| 200-Day Moving Average | 2.93 |
| 50-Day Moving Average | 1.65 |
| 20-Day Moving Average | 1.29 |
| 10-Day Moving Average | 1.40 |
| Average True Range | 0.18 |
| RSI (14) | 50.74 |
| ADX | 45.0 |
| +DI | 21.64 |
| -DI | 22.71 |
| Chandelier Exit (Long, 3 ATRs) | 1.33 |
| Chandelier Exit (Short, 3 ATRs) | 1.62 |
| Upper Bollinger Bands | 1.60 |
| Lower Bollinger Band | 0.97 |
| Percent B (%b) | 0.76 |
| BandWidth | 48.70 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.09 |
| MACD Histogram | 0.0508 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.72 | ||||
| Resistance 3 (R3) | 1.71 | 1.60 | 1.68 | ||
| Resistance 2 (R2) | 1.60 | 1.53 | 1.61 | 1.66 | |
| Resistance 1 (R1) | 1.53 | 1.49 | 1.48 | 1.54 | 1.64 |
| Pivot Point | 1.42 | 1.42 | 1.40 | 1.43 | 1.42 |
| Support 1 (S1) | 1.35 | 1.35 | 1.30 | 1.36 | 1.26 |
| Support 2 (S2) | 1.24 | 1.31 | 1.25 | 1.24 | |
| Support 3 (S3) | 1.17 | 1.24 | 1.23 | ||
| Support 4 (S4) | 1.18 |
